Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has initiated implementation of its strategic agreement with Fireblocks for crypto treasury management. Fireblocks, a leading digital asset custody platform, has facilitated over $10 trillion in secure transfers to date.
The partnership aims to establish institutional-grade infrastructure for buying, staking, and managing digital assets at scale. Fireblocks' multi-layer security framework incorporates multi-party computation technology, Intel SGX, a signature policy engine, and deposit address authentication network.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has partnered with Fireblocks as its institutional crypto treasury platform custodian. The strategic agreement aims to enhance Silo's digital asset management capabilities for Bitcoin, Ethereum, and Solana.
Fireblocks, which has facilitated over $6 trillion in secure transfers, will provide enterprise-grade security through its multi-layer framework, combining multi-party computation technology, Intel SGX, and deposit address authentication. This infrastructure will support Silo's long-term strategy for buying, staking, trading, and managing digital assets.
Silo Pharma (Nasdaq: SILO) has initiated its cryptocurrency treasury strategy with its first purchases of Ethereum (ETH) and Solana (SOL) tokens. The company, which operates as a developmental-stage biopharmaceutical and cryptocurrency treasury company, plans to stake these tokens for revenue generation and capital appreciation.
CEO Eric Weisblum expressed confidence in decentralized blockchain and DeFi platforms, highlighting the company's commitment to incorporating digital assets into its treasury holdings. This strategic move aims to support Silo's biopharmaceutical assets development while positioning the company for blockchain and real-world asset tokenization initiatives.
Silo Pharma (Nasdaq: SILO) has strengthened its intellectual property portfolio with a new Japanese patent (No. 7683882) granted to its research partner Columbia University for SPC-15, the company's lead PTSD treatment. The patent, which follows a recent Australian patent grant, covers serotonin 4 receptor agonists for stress treatment.
The intranasal PTSD treatment, exclusively licensed to Silo by Columbia University, gains additional international protection through this patent issuance, supporting the company's development and regulatory strategy for this novel therapy.
Silo Pharma (Nasdaq: SILO) has secured a significant patent in Australia (patent number 2020271839) for its PTSD drug candidate SPC-15. The patent, granted to Silo's research partner Columbia University, covers the invention "Prophylactic efficacy of serotonin 4 receptor agonists against stress" which is exclusively licensed to Silo.
SPC-15, the company's lead asset, is being developed as an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent strengthens Silo's global intellectual property portfolio and supports their plans for clinical trial development of this innovative therapeutic approach to preventing stress-induced disorders.
Silo Pharma (Nasdaq: SILO) announced the publication of preclinical research for its Alzheimer's disease therapeutic SPC-14 in the prestigious journal Alzheimer's Research & Therapy. The study demonstrates that SPC-14, a combination of (R,S)-ketamine with prucalopride, showed promising results in treating cognitive decline in Alzheimer's disease.
The research, co-authored by CEO Eric Weisblum, revealed that SPC-14 improved memory retrieval in mouse models. The therapeutic was developed under a sponsored research agreement with Columbia University, from which Silo obtained an exclusive global license in 2024 for development, manufacturing, and commercialization. The targeted Alzheimer's disease treatment market is projected to reach $30.8 billion by 2033, growing at a 18.8% CAGR.
Silo Pharma (Nasdaq: SILO) announced positive safety results for its PTSD drug candidate SPC-15 in a FDA-requested 7-day large animal safety study. The intranasal spray formulation demonstrated local and systemic safety with no toxicities at clinical-representative doses, showing comparable systemic exposure to standard oral administration.
The company is pursuing FDA approval through the 505(b)(2) pathway, which could streamline the approval process by leveraging existing safety data. Silo is currently conducting IND-enabling GLP toxicology studies and evaluating clinical trial sites. The PTSD market, valued at $1.8 billion in 2024, is projected to reach $3.2 billion by 2034.
Silo Pharma (Nasdaq: SILO) has announced a strategic expansion into cryptocurrency treasury management, focusing on Bitcoin, Ethereum, and Solana. The company has appointed crypto infrastructure expert Corwin Yu as the first member of its new Crypto Advisory Board to spearhead this initiative.
The strategy includes opportunistic digital currency purchases and yield generation through staking, supported by newly acquired AI-powered market intelligence technology. Simultaneously, Silo Pharma continues its biopharmaceutical focus, with its PTSD drug SPC-15 approaching FDA IND application submission.
Silo Pharma (Nasdaq: SILO) has completed dosing in a FDA-requested 7-day safety and toxicology large animal study for its lead PTSD drug candidate SPC-15. The bioanalytical and safety/toxicology results are expected within 60 days.
The company is progressing with two remaining preclinical studies: an IND-enabling GLP-compliant toxicology study and a device study for SPC-15's microchip-based nasal spray system. Silo plans to pursue the FDA's 505(b)(2) regulatory pathway for SPC-15's approval, which could potentially accelerate clinical timelines and reduce development costs.
Silo Pharma (Nasdaq: SILO) announced significant progress in the development of SPC-15, its novel intranasal PTSD drug candidate. The company expects to receive crucial preclinical study data within 30-90 days, including results from GLP-compliant toxicology studies and an FDA-requested safety study.
The company plans to submit an IND application by end of 2025, potentially leading to Phase 1 clinical trials in 2026. Silo intends to pursue the FDA's 505(b)(2) regulatory pathway to expedite development. Notably, SPC-15's unique approach targets stress resilience, differentiating it from existing PTSD treatments, in a market where no new drugs have been approved in nearly 25 years.